68ga-imp-288

Small moleculeexperimentalImaging agent

Clinical trial activity

1 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2013 (NCT01730638)

Timeline

2010s

  1. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetRadiopharmaceutical

    radiopharmaceutical

Chemistry & pharmacology

Imaging
68-gallium

Oral

No

Parenteral

No

Topical

No

Also known as

  • 68ga-imp-288

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01730638Phase 1/Phase 2 (Phase 2)Jan 1, 2013Immunomedics, Institut National de la Santé Et de la Recherche Médicale, France, University of Nantes
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ImmunomedicsFor profit1012013
Institut National de la Santé Et de la Recherche Médicale, FranceAcademic/Hospital1012013
University of NantesAcademic/Hospital1112013
3 organizations
Page 1 / 1